3BSA
| Crystal Structure of HCV NS5B Polymerase with a Novel Pyridazinone Inhibitor | Descriptor: | 2-({3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-(1,3-thiazol-5-yl)-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothia diazin-7-yl}oxy)acetamide, RNA-directed RNA polymerase | Authors: | Han, Q, Showalter, R.E, Zhao, Q, Kissinger, C.R. | Deposit date: | 2007-12-23 | Release date: | 2008-12-23 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine. Bioorg.Med.Chem.Lett., 18, 2008
|
|
3CDE
| Crystal structure of HCV NS5B polymerase with a novel Pyridazinone inhibitor | Descriptor: | N-{3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-thiophen-2-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide, RNA-directed RNA polymerase | Authors: | Zhao, Q, Showalter, R.E, Han, Q, Kissinger, C.R. | Deposit date: | 2008-02-26 | Release date: | 2009-03-03 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorg.Med.Chem.Lett., 18, 2008
|
|
4Y8X
| |
4Y8Z
| |
4Y8Y
| |
4PAR
| The 5-Hydroxymethylcytosine-Specific Restriction Enzyme AbaSI in a Complex with Product-like DNA | Descriptor: | 1,2-ETHANEDIOL, DNA 14-MER, DNA 18-MER, ... | Authors: | Horton, J.R, Cheng, X. | Deposit date: | 2014-04-09 | Release date: | 2014-06-25 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.89 Å) | Cite: | Structure of 5-hydroxymethylcytosine-specific restriction enzyme, AbaSI, in complex with DNA. Nucleic Acids Res., 42, 2014
|
|
2VD7
| Crystal Structure of JMJD2A complexed with inhibitor Pyridine-2,4- dicarboxylic acid | Descriptor: | JMJC DOMAIN-CONTAINING HISTONE DEMETHYLATION PROTEIN 3A, NICKEL (II) ION, PYRIDINE-2,4-DICARBOXYLIC ACID, ... | Authors: | Ng, S.S, von Delft, F, Pilka, E.S, Kavanagh, K.L, McDonough, M.A, Savitsky, P, Arrowsmith, C.H, Weigelt, J, Edwards, A, Sundstrom, M, Schofield, C.J, Oppermann, U. | Deposit date: | 2007-10-01 | Release date: | 2007-11-27 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J. Med. Chem., 51, 2008
|
|
7D3M
| |
7D3K
| |
7D3R
| |
7D3L
| |
6ADM
| |
6ADL
| |
6ADR
| |
6ADS
| Structure of Seneca Valley Virus in acidic conditions | Descriptor: | VP1, VP2, VP3, ... | Authors: | Lou, Z.Y, Cao, L. | Deposit date: | 2018-08-02 | Release date: | 2019-02-06 | Last modified: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (2.84 Å) | Cite: | Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1 Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6ADT
| Structure of Seneca Valley Virus in neutral condition | Descriptor: | VP1, VP2, VP3, ... | Authors: | Lou, Z.Y, Cao, L. | Deposit date: | 2018-08-02 | Release date: | 2019-02-06 | Last modified: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (3.22 Å) | Cite: | Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1 Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
5QQP
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | Authors: | Sheriff, S. | Deposit date: | 2019-05-20 | Release date: | 2019-09-18 | Last modified: | 2021-05-12 | Method: | X-RAY DIFFRACTION (2.08 Å) | Cite: | Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. Bioorg.Med.Chem.Lett., 29, 2019
|
|
5QQO
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, MET-ASP-ASP-ASP-ASP-LYS-MET-ASP-ASN-GLU-CYS-THR-THR-LYS-ILE-LYS-PRO-ARG, ... | Authors: | Sheriff, S. | Deposit date: | 2019-05-20 | Release date: | 2019-09-18 | Last modified: | 2021-05-12 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. Bioorg.Med.Chem.Lett., 29, 2019
|
|
7FEI
| Complex of FMDV A/WH/CHA/09 and bovine neutralizing scFv antibody R55 | Descriptor: | Capsid protein VP0, IG HEAVY CHAIN VARIABLE REGION, IG LAMDA CHAIN VARIABLE REGION | Authors: | He, Y, Li, K, Lou, Z. | Deposit date: | 2021-07-20 | Release date: | 2021-09-29 | Last modified: | 2022-02-16 | Method: | ELECTRON MICROSCOPY (3.91 Å) | Cite: | Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization. J.Virol., 95, 2021
|
|
7FEJ
| Complex of FMDV A/AF/72 and bovine neutralizing scFv antibody R55 | Descriptor: | A/AF/72 VP1, A/AF/72 VP2, A/AF/72 VP3, ... | Authors: | He, Y, Li, K, Lou, Z. | Deposit date: | 2021-07-20 | Release date: | 2021-09-29 | Last modified: | 2022-02-16 | Method: | ELECTRON MICROSCOPY (3.91 Å) | Cite: | Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization. J.Virol., 95, 2021
|
|
5CMZ
| Artificial HIV fusion inhibitor AP3 fused to the C-terminus of gp41 NHR | Descriptor: | 1,2-ETHANEDIOL, 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE, Artificial HIV entry inhibitor AP3, ... | Authors: | Zhu, Y, Ye, S, Zhang, R. | Deposit date: | 2015-07-17 | Release date: | 2015-09-16 | Method: | X-RAY DIFFRACTION (2.574 Å) | Cite: | Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Sci Rep, 5, 2015
|
|
5CN0
| Artificial HIV fusion inhibitor AP2 fused to the C-terminus of gp41 NHR | Descriptor: | DI(HYDROXYETHYL)ETHER, Envelope glycoprotein,AP2, MAGNESIUM ION | Authors: | Zhu, Y, Ye, S, Zhang, R. | Deposit date: | 2015-07-17 | Release date: | 2015-09-16 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.901 Å) | Cite: | Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Sci Rep, 5, 2015
|
|
5CMU
| |
5QCK
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid | Descriptor: | 1,2-ETHANEDIOL, 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid, Coagulation factor XI, ... | Authors: | Sheriff, S. | Deposit date: | 2017-08-10 | Release date: | 2017-11-08 | Last modified: | 2018-02-21 | Method: | X-RAY DIFFRACTION (2.64 Å) | Cite: | Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). J. Med. Chem., 60, 2017
|
|
7CQH
| Complex of TRP_CBS2 and Calmodulin_Clobe | Descriptor: | AT15141p, CALCIUM ION, Transient receptor potential protein | Authors: | Shen, Z.S. | Deposit date: | 2020-08-10 | Release date: | 2021-06-23 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Calmodulin binds to Drosophila TRP with an unexpected mode. Structure, 29, 2021
|
|